<DOC>
	<DOCNO>NCT02288208</DOCNO>
	<brief_summary>This study evaluate addition birinapant subject chronic Hepatitis B currently receive anti-viral therapy either tenofovir entecavir . Patients receive either birinapant placebo addition anti-viral therapy .</brief_summary>
	<brief_title>Phase I Safety Tolerability Study Birinapant Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Documented history chronic Hepatitis B infection currently treat tenofovir entecavir least 3 month Measurable titer HBsAg HBV DNA level &lt; 2 log copies/mL 10² copies/mL No ChildPugh score 5 plus valid FibroScan® least 10 reading median score &lt; 7 interquartile range &lt; 30 % Adequate liver function , aspartate AST ALT ≤2 x ULN Adequate renal function evidence creatinine ≤2 mg/dL Participation interventional study within 4 week prior Screening Known HIV infection , Hepatitis C , significant hepatic disorder include cirrhosis ( ChildPugh Class B C ) Serious illness autoimmune disease know liver disease Uncontrolled hypertension Impaired cardiac function , uncontrolled cardiac arrhythmia despite medication , clinically significant cardiac disease Currently breast feeding , pregnant plan become pregnant Known allergy hypersensitivity formulation component birinapant placebo , include citric acid History cranial nerve palsy Current treatment antiTNF therapy receive treatment antiTNF therapy within last 6 month Use nonsteroidal antiinflammatory drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>